Immutep Ltd Stock Australian S.E.
Equities
AU000000PRR9
Biotechnology & Medical Research
Sales 2024 * | 3.11M 2.11M | Sales 2025 * | 4.57M 3.1M | Capitalization | 506M 343M |
---|---|---|---|---|---|
Net income 2024 * | -46M -31.2M | Net income 2025 * | -56M -37.98M | EV / Sales 2024 * | 113 x |
Net cash position 2024 * | 154M 104M | Net cash position 2025 * | 105M 70.99M | EV / Sales 2025 * | 87.8 x |
P/E ratio 2024 * |
-9.65
x | P/E ratio 2025 * |
-8.37
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.92% |
Managers | Title | Age | Since |
---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 51 | 10-12-31 |
David Fang
DFI | Director of Finance/CFO | - | 18-02-28 |
Florian Vogl
CTO | Chief Tech/Sci/R&D Officer | - | 23-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Russell Howard
CHM | Chairman | 74 | 13-05-07 |
Marc Voigt
CEO | Chief Executive Officer | 51 | 10-12-31 |
Anne Anderson
BRD | Director/Board Member | - | Feb. 13 |
1st Jan change | Capi. | |
---|---|---|
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |